Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling

Executive Summary

Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
Advertisement

Related Content

Exelon Dementia Indication May Revive Flagging Sales, Novartis Says
Novartis To Maintain Sales Force In Face Of Potential Competitor Cutbacks
Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority
Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority
FDA Sends Mixed Message On Labeling Authority: Is Website Enough?
Protopic, Elidel Need “Black Box” Warning On Cancer Risk, FDA Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS046779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel